

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	H Matthews	
	N Menezes	
	N Mumford	
	S Krag	
	H Goodfellow	
	L Condrón	
	D Georgiou	
	R Legg	
	C Carter	
	E Cowan	(Appointed 24 August 2021)
	N Longworth	(Appointed 27 August 2021)
	L Nylander	(Appointed 24 August 2021)
Secretary	G Brown	
Charity number (England and Wales)	1137689	
Charity number (Scotland)	SC049777	
Company number	07272699	
Registered office	Unit 9 Oakhanger Farm Business Park Oakhanger Road Oakhanger Hampshire GU35 9JA	
Auditor	Alliotts LLP Friary Court 13-21 High Street Guildford Surrey GU1 3DL	

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1 - 2
Trustees' report	3 - 14
Statement of Trustees' responsibilities	15
Independent auditor's report	16 - 19
Statement of financial activities	20
Balance sheet	21
Statement of cash flows	22
Notes to the financial statements	23 - 35

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

2021 was also a year of uncertainty as the pandemic was very much still with us. However, as a small and nimble organisation, we were able to flex our activities to take account of restrictions that were happening across the UK.

We started with a new concept – Jog Jan for Pan Can – allowing people to give themselves their own running or walking target for the month whilst getting friends and relatives to sponsor them. This raised an incredible £140,000.

We were hoping to do a PC Aware Wales campaign in 2020, but it was not only postponed to 2021, but due to the pandemic we had to flex it to accommodate the lockdowns. All assets were developed in Welsh and English and the campaign involved raising awareness to the public, GPs and Pharmacists.

We ran two TV awareness campaigns which resulting in increased visits to the symptoms pages of our website and we were heavily involved in the development of the ITV Tonight documentary on pancreatic cancer.

We further developed our Action on the Ground pilot in Glasgow and in Pancreatic Cancer Awareness Month, we translated many of our awareness assets into the 6 key foreign languages spoken in the UK.

We have also been extremely active in the policy arena with a debate in the Scottish Parliament and submitting evidence to the Health & Social Care Select Committee. We have also been attending many NHS England and Scotland meetings to assess the impact the pandemic has been having on our patient cohort and teaming up with other coalitions such as One Cancer Voice and Cancer 52 to spread our messages further.

We continued with our research project at the University of Surrey looking at patient records of people with diabetes who went on to get pancreatic cancer and those who did not. The aim is to identify a group of new-onset diabetes patients who could potentially be at risk of pancreatic cancer and to help GPs know when to refer a patient with new-onset diabetes for pancreatic cancer testing in the hope they can be diagnosed early.

We continued to provide advice and information relating to COVID-19, cancer services, but we at Pancreatic Cancer Action (PCA) kept on top of it by attending many (virtual) meetings with NHS, Governments and collaborating with other charities and organisations to share information.

Using these channels, we continued to update our website and social media channels daily to give our patients and their families the most up-to date information we could.

The long-term impact of reduced public presentation to primary care and reduced urgent referrals at the height of the pandemic has not yet been fully realised. The missed and delayed cohort of cancer patients not yet recorded will have come through alongside incident cancer cases, adding to diagnostic and treatment demand. These people will naturally be presenting at a later stage and so are more likely to be, or become, inoperable, due to diagnostic delays and reduced investigative capacity. The impact of revised treatment pathways during the first wave of the pandemic is just coming through with one specialist centre reporting a doubling of mortality.

We will continue to be a voice for patients and families to ensure pancreatic cancer is a focused priority in NHS Recovery Plans.

We are so very grateful to our wonderful supporters and fundraisers who have not only stuck with us but helped us increase income to near normal levels.

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

In 2020 we started the development of a project to look at the underserved groups in the UK who have a poorer prognosis when diagnosed with pancreatic cancer. We not only want to understand why, but we want to ensure all our information is communicated effectively and that we reach these groups to ensure they take action when presenting with symptoms.

We had great plans to celebrate our 10th anniversary in 2020 by launching our new vision for the future in what we hope will be the 'Decade of Change' for pancreatic cancer.

We are very proud of our achievements to date and we will continue to have a primary focus of improving early diagnosis of pancreatic cancer as well as ensuring all those affected by pancreatic cancer have access to the care, information and support they need.

However, we can't do all this alone and we are so fortunate to have so many Community Representatives, Action Ambassadors and other volunteers who help in a variety of ways including providing us with lay reviews for our patient information. We rely heavily on their generosity of time as well as their efforts to raise awareness and fundraise in their localities.

Some of our key volunteers are our Trustees, who have supported me and my team so very well over the past year.

I am also grateful to our wonderful Patrons and Ambassadors who help us with our activities and support our campaigns and of course to our marvellous fundraisers and donors, without whom, we couldn't do what we do.



Ali Stunt (Sep 9, 2022 16:12 GMT+1)

.....
Ali Stunt
Founder & Chief Executive
Dated: 09/09/2022

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees present their annual report and financial statements for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

- A Awareness** - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis
- C Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer
- T Train** and provide pioneering educational resources for our medical and healthcare communities
- I Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes
- O Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer
- N Now** – we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet annually to develop a strategy to meet the charitable objectives. Once the overall strategy has been agreed by the Trustees a series of operational meetings attended by a selection of the Trustees and employees, who the Trustees believe have relevant skills and experience in the specific area look at the operational implementation.

The Trustees currently have a range of skills and experience that range from medical/scientific, Legal, corporate governance, finance and PR.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Role of volunteers

The Charity receives the very welcome assistance of volunteers. To date this has usually been for specific projects or fund-raising initiatives. In 2021 our network of Regional Representatives across the UK was made up of 50 volunteers. The aim is that these volunteers represent Pancreatic Cancer Action, raise awareness of pancreatic cancer and fundraise in their communities.

The pandemic and ever-changing restrictions has impacted how volunteers can assist in our office, at events or within their communities, but we continue to evolve ways to enable people show their support. The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

Achievements and performance

1. Awareness - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

STV Advert

In April 2021 we re-ran the TV awareness advert featuring one of our amazing supporters, Gavin Oattes talking about the symptoms of pancreatic cancer and how he sadly lost his dad to the disease. This advert was due to be scheduled for January 2021, but because of the sensitivities surrounding the pandemic and the winter pressures on the NHS, we delayed until April.

During the month we saw a 60% increase in visits to our symptoms pages on our website versus the previous month, despite the advert only being shown in Scotland.

PC Aware Wales

Due to launch in June 2020, this public and healthcare professional awareness campaign had to be put on hold until June 2021 due to Covid-19 lockdown restrictions.

Pancreatic cancer is the 16th most common cancer in Wales, affecting around 500 annually. It is the 6th biggest cancer killer, with 505 deaths. Incidence and mortality can be examined by health board. However, these results may mislead, as the size of health board, and demographic varies widely across the country. Many areas in Wales have a five-year survival rate of only three per cent (versus 7.3% UK wide).

We conducted a pre-campaign survey which found that 75% of the 1,000 Welsh people surveyed, reported that they know "nothing" (21.6%) or "almost nothing" (53.4%) about pancreatic cancer.

We delivered GP resource packs to 297 GP surgeries and Pharmacy packs to 256 community pharmacies and dropped 110,000 symptom awareness leaflets into people's homes in Denbighshire, Wrexham, Caerphilly, Newport, Merthyr Tydfil and Rhondda Cyon Taf.

By targeting all key stakeholders in the same region within the same time frame we hoped to significantly increase awareness of pancreatic cancer and save lives through early diagnosis.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) **FOR THE YEAR ENDED 31 DECEMBER 2021**

ITV Tonight Documentary

In October 2021, Daniel Kennedy, a well-known documentary film maker turned his lens to something close to his heart; his father, Paul, passed away from pancreatic cancer just three months after he was diagnosed. Whilst being treated at the height of the pandemic, Daniel captured Paul's most precious moments through the course of his final journey.

Daniel came to become familiar with Pancreatic Cancer Action in June last year after receiving support from Pancreatic Cancer Action's Founder & CEO, Ali Stunt. For many years charities like ours, have tried to cut through the noise to increase awareness of the 5th biggest cancer killer in the UK.

With this documentary for the ITV Tonight current affairs programme, Daniel focused a spotlight on the deadliest common cancer. He investigated whether enough is being done to get patients diagnosed early. During the documentary we saw interviews with professors, doctors, charity CEOs and our very own 14-year survivor and Founding CEO of Pancreatic Cancer Action, Ali Stunt. Speaking on the program, Ali opened up about how "Pancreatic cancer survivors over ten years can't remain in the 1% statistic. This is a very lonely place to be,".

Islets of Silence – The C Word

A play written and directed by Isobel Barrett of Tram Direct Theatre Company was set to tour around theatres in Scotland in 2020 to help raise awareness of pancreatic cancer through the arts.

Originally funded by PCS alongside Culture & Business Fund Scotland match funding by Arts & Business Scotland, the project launch in 2020 attracted fantastic media coverage including STV News.

The tour was postponed due to the pandemic, but Isobel and the production team continued to create innovative ways to use the arts to raise awareness, with excerpts of the play filmed and shared via social media.

In September/October 2021 the Islets of Silence play was able to tour again to great acclaim.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Pancreatic Cancer Awareness Month

Throughout the month of November we had an extra push on raising awareness of the symptoms of pancreatic cancer to reach more people than we ever have before. This started at the beginning of the month and we saw an incredible amount of social media shares of our symptoms posts.

Key highlights:

Translation of assets:

In 2021 we embarked on a project to provide digital access to our Symptoms poster, Fact's poster, Risks poster, Symptom's diary, the poster for our Patient Information Booklets and About us leaflet. Translated into 6 languages: Polish, Punjabi, Urdu, Bengali, Gujarati, Arabic. These assets are hosted on their own translated landing pages on our website.

We want to use this initiative to make our resources more accessible to ethnic minorities in the UK and individuals who have the symptoms or are at risk of pancreatic cancer and to develop it further in 2022.

Leaflet drop in Burnley

We conducted a PC aware style leaflet drop across 31,000 households in Burnley on 15th November 2021.

Burnley is recognised as an area of high deprivation, making it important for us to target communities in this area.

We used the leaflet to promote awareness of who we are and the signs and symptoms of pancreatic cancer.

National TV Campaign

We developed a 20 second commercial across some of the ITV portfolio including, STV, ITV Borders, ITV2 and ITV3 for maximum reach of our core demographic (men and women over the age of 45).

Turn it Purple campaign.

We continued our Turn it Purple campaign and in 2021 sent out over 150 packs to supporters.

Purple Lights UK

The collaborative campaign Purple Lights UK saw locations across the country light up purple to raise awareness during November and in particular on World Pancreatic Cancer Day. This is largely a supporter focused campaign and this year we saw lots of supporters light up their own homes in support as well as buildings and landmarks.

Broadcast Media

Press coverage in 'The Sun', 'Daily Express', 'Daily Mirror', 'Daily Record', local news outlets for the campaign such as 'Northern Daily Echo', Farnham Herald, The Exeter Daily' and more. And STV news coverage in Scotland with Survivor Debra Grindall & PCA Team member Nicky McManus.

Action on the Ground (AoG)

During 2019 PCA started to research and define its approach to communicating with groups that have low health literacy, groups that are hard to reach with the worst outcomes in relation to diagnosis and survival of pancreatic cancer.

AoG kicked off its work in east end of Glasgow, one of the highest areas of deprivation in not only Scotland but the whole of the UK. Research suggests this community has some of the lowest health literacy, an increase in barriers to presentation and are exposed to a higher rate of the risk factors associated with pancreatic cancer than other communities.

In 2021 we have taken a proactive approach to reach this community and provide them the education and support relating to catching pancreatic cancer early. AoG has developed a number of relationships with trusted partners to carry out this work. This includes the Scottish Pantry Network where we conducted a survey of service users' knowledge of pancreatic cancer, followed by us distributing a specialist easy-to-read leaflet with symptoms with every food parcel that went out and the Scottish Pantry Network promoting our health information booklets including our recipe book. We are currently waiting on the results of a second survey with service users to see if this has increased their understanding of the signs and symptoms of pancreatic cancer.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.

Scottish Parliament Engagement

We engaged with politicians across the UK to raise awareness of the statistics around pancreatic cancer and the importance of early diagnosis.

As part of our ongoing plan to engage, lobby and influence decisions makers we wrote to all MSPs to re-introduce ourselves and explain our operations in Scotland.

We supported Clare Adamson MSP in securing a debate in the Scottish Parliament in Pancreatic Cancer Awareness Month. The motion achieved cross-party support from over 40 MPs/MSPs.

On World Pancreatic Cancer Day, our Scottish team parked the Pan Can Van outside Scottish Parliament and 29 parliamentarians came to the van to discuss issues surrounding pancreatic cancer.

In Scotland, we continued to engage with key stakeholders, including representation at meetings and discussions with The Scottish Cancer Coalition, Cross Party Group on Cancer, The Scottish HPB Network and various other networks and contacts.

Westminster Engagement

We had hoped to have an in-person meeting at the Palace Of Westminster on 29th November but unfortunately, due to covid restrictions, members of the public were not allowed onto the Parliamentary estate, so we had to cancel our plans. Hopefully we can reschedule this for 2022.

Furthermore, we wrote to every MP across the UK, asking them to support PCA in November's awareness month and use our resources to raise awareness of pancreatic cancer.

Health & Social Care Select Committee

The House of Commons Health & Social Care Select Committee conducted an investigation into why cancer outcomes in England continued to lag behind comparable countries internationally and examined evidence submitted relating to the underlying causes of these differences. They also collated evidence on the impact and disruption to cancer services during the covid-19 pandemic, the efforts to catch up, and ask whether the ambitions set out in the NHS Long Term Plan would help close the gap with the best performing countries worldwide.

PCA submitted written evidence highlighting the key challenges to improving pancreatic cancer survival rates and made clear recommendations on changes required. These recommendations focused on workforce planning, equipment, education and empowering health care professionals. The full report can be found here: <https://committees.parliament.uk/work/1377/cancer-services/publications/written-evidence/?page=2>

We continue to lobby members of the select committee to take oral evidence sessions from third sector organisations and patient groups.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

All Party Parliamentary Group on Pancreatic Cancer

Unfortunately, due to the pandemic, the APPG PC was unable to function as usual. However, we did put into motion an inquiry into the impact that Covid-19 has had on pancreatic cancer diagnosis and treatments. This report was published in 2021.

In 2022, Pancreatic Cancer Action will be taking over as secretariat for the APPG PC.

Local Government Engagement

All local authorities have responsibilities concerning public health and the promotion of health and wellbeing. Their powers and responsibilities vary depending on whether they are a county council, district council, unitary authority, metropolitan borough, London boroughs, Welsh unitary, Scottish unitary.

We are working with local authorities across the UK to pass motions in Council Chambers relating to pancreatic cancer. A standard motion would include requirements for the Council to host our occupational health e-learning, host information relating to pancreatic cancer on their website, display symptoms posters in their public buildings such as libraries, support care staff in commissioned services with training for staff to recognise the symptoms of pancreatic cancer amongst their residents, light up local landmarks purple for PCAM. Outside of the motions are working with Councillors who are part of their local Health scrutiny committee to request reports into local cancer services.

The first motion went to East Hampshire Council on November 11th.

Cancer Alliances

We have worked more closely than ever before with cancer alliances and those running cancer services across the UK. We collaborated with Surrey and Sussex Cancer Alliance to raise awareness and promote our services among GPs and pharmacists. Alongside this, we worked with the Lancashire and South Cumbria Cancer Alliance to raise awareness with GPs, hospitals and the public. As a result of this, we were able to promote our E-learning modules to help health care professionals diagnose pancreatic cancer early as well as raising awareness in local communities.

3. Train and provide pioneering educational resources for our medical and healthcare communities.

Health Care Professional Engagement

Ongoing work is taking place to provide resources and educate health care professionals on pancreatic cancer and how to support their patients. Current work includes:

GP Link letter – Around 400 letters were hand-delivered to GP practices across Scotland. The letter included information about our GP e-learning as well as symptom awareness posters.

Pharmacy Bags – Following their success in our PC Aware Wales campaign, 100,000 pharmacy bags were given to pharmacies in the Early Cancer Diagnostic Centre pilot areas designated by the Scottish Government. These are in Ayrshire & Arran, Dumfries & Galloway and Fife. Pharmacy bags also went out in the east end of Glasgow to support the Action on the Ground project.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

New e-learning

Work has been undertaken to develop new e-learning for allied health care professionals. A key area of focus has been about what happened to those who are misdiagnosed and where are they referred. As a result, work had begun on new e-learning for physiotherapists. The Chartered Society of Physiotherapy have agreed to accredit, host and promote the new e-learning. Discussions are also taking place to see if this e-learning can be tweaked for chiropractors and if there is a professional body interested in partnering with us.

GP Advisory Committee

Recruitment is currently taking place for a PCA GP Advisory Committee. We are committed to ensuring it provides the highest quality possible support and resources for both healthcare professionals and patients. The value and importance of involving GPs in the development, delivery, and promotion of our services and support to patients, through an Advisory Committee sitting under the Trustee Board.

4. Innovative research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.

Research Strategy

Following meetings with the Scientific Sub-committee of the Trustee Board and the Association of Medical Research Charities it has been agreed that we develop a new 'Research strategy' for the organisation. This new strategy will set out our priorities, processes for making awards and be a key part of how we make the decade of change a reality.

Diabetes and pancreatic cancer

Pancreatic Cancer Action is committed to funding early diagnosis research projects. Our past early diagnosis challenge award gave funding to researchers primarily working with biomarkers that has led to further investment from Pancreatic Cancer Research Fund (PCRF) and Cancer Research UK. Throughout 2021 and beyond we are funding projects examining the link between diabetes and pancreatic cancer. Research is emerging in this area that suggests there may be an opportunity for early diagnosis of pancreatic cancer in patients with new diabetes. The University of Surrey research project exploring if BMI and glycated haemoglobin (HbA1c) are markers for pancreatic cancer is making good progress. The project is due to come to an end late 2022.

Precision-Panc

We continue to engage and support the ground-breaking Precision-Panc project led from The University of Glasgow.

Majority funded by Cancer Research UK, the Precision-Panc platform was founded in 2017, bringing together expertise in pancreatic cancer from universities, research institutes and the NHS.

Precision medicine is about tailoring treatments to an individual's cancer and the overall aim is to make this a reality for more people with pancreatic cancer – through building knowledge that will ultimately allow clinicians to match patients with the most suitable treatment.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

There is now a UK wide network of over 30 hospitals that can offer precision medicine clinical trials as a vital treatment option for people with pancreatic cancer. As part of the wider Precision-Panc programme tissue samples are also collected from participants for molecular profiling, which could lead to vital new insights into the development of the disease in the future.

In Precision-Panc all registered patients have their genome testing using Glasgow Precision Oncology Laboratories bespoke panel. Networked clinical trials with researchers across the country share expertise and knowledge, as well as creating and sharing infrastructure, leading to trials which are quicker to set up and recruit.

This ambitious programme of research could transform how pancreatic cancer is treated and as we learn more about the disease, pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.

PCA are proud to work closely with the Precision-Panc team with our Founder and CEO Ali Stunt currently sitting on the Precision Panc Steering Committee. We share and contribute knowledge and experiences and work collaboratively to improve access to clinical trials. We provide additional resource by fully funding a dedicated pancreatic cancer clinical nurse specialist within the West of Scotland Cancer Network.

5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer

PCS Precision-Panc, Pancreatic Cancer Clinical Nurse Specialist

Sine our merger with Pancreatic Cancer Scotland in March 2020, we have taken over fully funding an innovative new dedicated pancreatic cancer nurse specialist role with NHS Greater Glasgow and Clyde to support the West of Scotland Pancreatic Team, Precision-Panc and our charity.

Based at Glasgow Royal Infirmary the post-holder provides supplementary direct clinical support for patients and carers, ensuring there is a point of contact for information and advice, before, during and after treatment. A large part of this includes signposting individuals to appropriate support services and guiding them through a complex pathway. This is key in facilitating holistic treatment throughout a patient's journey, recognising every individual is different.

While this is not a research nurse post, the unique combined research aspect of this role supports patients and families understanding of clinical trials and has contributed to enhancing participation and recruitment of patients to the Precision-Panc study and other trials, which are key to improving survival in the future.

We are delighted with how the role has adapted and evolved – joining everything together with the patient at the heart of it. The success of this role demonstrates how a collaborative approach with the third sector, healthcare professionals and research programmes can make a real difference - especially in ensuring patients and families are provided with support and information.

We are currently exploring the opportunity of a second CNS post for NOSCAN/NHS Grampian/Highland. Further discussions have taken place with Ross Carter, Elspeth Cowan, Fiona Brown and Chrissie Lane, Consultant Nurse for Cancer Care within NHS Highland to understand the geographical differences, complexities and needs for The North. A post within NHS Highland is being scoped which could potentially be part time.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Patient Information Booklets

Our booklets contain the most up to date information available to help patients to understand pancreatic cancer, treatment options and the experience of the disease.

We are very grateful to our peer and lay reviewers who have given their time to ensure our information is evidence based, accurate and understandable.

The booklets are easy to understand at any stage of the patients journey and are available to order or view online.

Patient Information Forum (PIF) Audit

PIF TICK on our leaflets, websites or videos shows and our health information has been through a professional and robust production process. Due to recent recruitment, a review took place in November where we were issued a certificate of certification for six months before a full audit in Summer 2022. The team are using this as an opportunity to update all our processes relating to the production of health information to ensure they are both as streamlined and robust as possible.

Support

Our help and support section of our website is designed to help everyone that is affected by pancreatic cancer to help answer any questions people may have.

Our website contains helpful information and links to support, from the moment symptoms first appear, treatment, coping and bereavement.

Our sources of support includes an interactive option to engage with our partners at Grief Chat. GriefChat is a safe space for grieving or bereaved people to be able to share their story, explore their feelings and be supported by a qualified bereavement counsellor.

We are proud to continue our partnership with Cancer Support Scotland (CSS), funding support services for anyone affected by pancreatic cancer in Scotland. This includes the person diagnosed, their family, friends, carers and those who have lost a loved one.

We will continue to develop relationships with stakeholders to ensure that there is support available throughout the UK as we listen to the needs of patients and families.

Wider activities and engagement:

Conferences and Exhibitions

Due to the pandemic, we were only able to attend the Pharmacy Show in October 2021

PCA Action Ambassadors

We will continue to recruit further patients or carers who have had experience of pancreatic cancer as regional representatives in areas where we currently do not have representation.

Fundraising

Actions were taken to review fundraising activities that could be pivoted to virtual events and products which meant income continued to be received.

Increasing supporter engagement was top of the agenda during 2021 and we have worked hard as a team to make sure that all supporters have been communicated with accordingly throughout. We have hosted Zoom calls, made personal phone calls and have sent newsletters and the Action Post to keep them updated.

With the lens of the pandemic in mind, we were fairly conservative in our targets for fundraising

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Challenge events

We continued to focus on virtual events and in January launched Jog Jan for Pan Can. This was particularly well received and raised over an incredible £140,000 for us which was an excellent start of the year.

Challenge events were more challenging as lock downs meant we weren't sure any would take place. However, the London Marathon did take place. Other challenge events included the London Landmarks Half Marathon, the Manchester Marathon, The Kiltwalk (which included a very generous 50% top up on income raise by Sir Tom Hunter).

We would like to say a big thank you to all our fantastic supporters, without whom we would not be able to carry out our vital work. This year they have adapted to run, walk, and cycle locally and take on new challenges, with virtual activities and online fundraising taking place across the country and taking on in-person events when the country opened up again.

Community Fundraising

Notable community fundraising included £40,000 raised by the Freemasons of Glasgow over a five year period.

Lord Margadale and his family opened their gardens at Fontill House and ran a silent auction in memory of his dear friends' Charlie Barton and Louise Eadie's mother who sadly passed away from pancreatic cancer. The event raised a huge £53,000

Luzija Dance raised an incredible £3,000 in July at her family fun day despite being just 16 years old. Luzija has lost an uncle and Grandad to PC and her Grandma was undergoing treatment at the time. Luzija set out to plan this event with her parents however quickly showed she had the determination to plan the whole event. Over 100 people from around her local community attended. From bouncy castles to local stall holders, Luzija was able to source all at very little cost meaning she was able to raise such a fantastic amount.

Charlie Creagh- Barry has raised over £9,000 for PCA after losing his mum in May. We were privileged to meet Charlie and his sister Millie at Fonthill after they found a flyer for the event when sorting through his mum's possessions. Charlie took on a gruelling army style challenge for 30 days across the summer raising over £7,000 and a further £1500 being donated following his mums funeral. Charlie has since got his workplace involved (Sav UK) and is hoping to raise even more for PCA in the future.

The support from our community fundraisers is, as ever, invaluable and we have seen supporters dye their hair, hold online concerts and quizzes to help us with our work. Thank you – we are so very grateful for all you do, then, now and in the future.

Action funds:

At the end of 2021, we had the following action funds:

- Action for Pat and Paul (Scotland)
- Hope is Contagious
- The Shaun Wright Foundation (NE England)

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Corporate partnerships and support

We have invested in developing relationships with businesses both large and small and are delighted to have been able to partner and receive support from such passionate people in 2021. Our corporate partners play a vital role in allowing us to raise more awareness and funds for pancreatic cancer and we can't thank them enough for their support.

They work with us in various capacities and for various lengths of time and in 2021 we were supported by:

- Pen Underwriting
- Sheila Fleet Jewellery
- Just Employment Law
- Partick Thistle Football Club
- Tunnocks
- Arnold Clark Car & Van Rental

Just Employment Law has continued to give us phenomenal support. In Pancreatic Cancer Awareness Month their online auction raised a whopping £73,000!

Trusts and Grants

We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2021 these included grants from:

Restricted

Pavers Foundation £2,000

Unrestricted:

None

Financial review

The results for the year are summarised in the Statement of Financial Activities on page 19.

The Trustees are pleased to report that the charity's incoming resources for 2021 amounted to £754,217 (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £513,874 (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

Primarily as a result of these activities, the charity achieved a net loss for the year of -£87,740 (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2021, the charity held reserves of £842,197 of which £474,887 was restricted. Free reserves stood at £362,118, which is in line with the level of the reserves policy established by the board.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews

N Menezes

N Mumford

S Krag

H Goodfellow

L Condron

D Georgiou

R Legg

A Clancy

(Resigned 14 April 2021)

C Carter

E Cowan

(Appointed 24 August 2021)

N Longworth

(Appointed 27 August 2021)

L Nylander

(Appointed 24 August 2021)

None of the Trustees has any beneficial interest in the charity. There are five members of the company who guarantee to contribute £10 in the event of liquidation. The following trustees are members: H Matthews, N Menezes and C Carter.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Auditor

In accordance with the company's articles, a resolution proposing that Alliot's LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

Nicola Mumford

Nicola Mumford (Sep 9, 2022 16:11 GMT+1)

.....
N Mumford

Chair of Trustees

Dated: 09/09/2022..

PANCREATIC CANCER ACTION

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

Extent to which the audit was considered capable of detecting irregularities, including fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS AND TRUSTEES OF PANCREATIC CANCER ACTION

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body, and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

09/09/2022

.....

Chartered Accountants
Statutory Auditor

Friary Court
13-21 High Street
Guildford
Surrey
GU1 3DL

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Income from:							
Donations and legacies	3	725,410	21,790	747,200	532,104	623,639	1,155,743
Charitable activities	4	-	-	-	-	92,236	92,236
Other trading activities	6	6,963	-	6,963	7,697	-	7,697
Investments	5	54	-	54	801	-	801
Total income		732,427	21,790	754,217	540,602	715,875	1,256,477
Expenditure on:							
Raising funds	7	328,083	-	328,083	270,766	37,849	308,615
Charitable activities	8	346,437	167,437	513,874	312,399	125,439	437,838
Total expenditure		674,520	167,437	841,957	583,165	163,288	746,453
Net income/(expenditure) for the year/							
Net movement in funds		57,907	(145,647)	(87,740)	(42,563)	552,587	510,024
Fund balances at 1 January 2021		309,403	620,534	929,937	351,966	67,947	419,913
Fund balances at 31 December 2021		367,310	474,887	842,197	309,403	620,534	929,937

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Fixed assets					
Tangible assets	13		3,117		18,571
Current assets					
Stocks	14	18,411		14,892	
Debtors	15	50,577		113,325	
Cash at bank and in hand		822,729		840,651	
		891,717		968,868	
Creditors: amounts falling due within one year	16	(52,637)		(57,502)	
Net current assets			839,080		911,366
Total assets less current liabilities			842,197		929,937
Income funds					
Restricted funds	18		474,887		620,534
<u>Unrestricted funds</u>					
Designated funds	20	2,075		15,485	
General unrestricted funds		365,235		293,918	
			367,310		309,403
			842,197		929,937

09/09/2022

The financial statements were approved by the Trustees on

Nicola Mumford

Nicola Mumford (Sep 9, 2022 16:11 GMT+1)

.....
N Mumford
Trustee

Company Registration No. 07272699

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	24		(17,975)		532,890
Investing activities					
Investment income received		53		801	
		<hr/>		<hr/>	
Net cash generated from investing activities			53		801
Net cash used in financing activities			-		-
			<hr/>		<hr/>
Net (decrease)/increase in cash and cash equivalents			(17,922)		533,691
Cash and cash equivalents at beginning of year			840,651		306,960
			<hr/>		<hr/>
Cash and cash equivalents at end of year			822,729		840,651
			<hr/> <hr/>		<hr/> <hr/>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

Charity information

Pancreatic Cancer Action is a private company limited by guarantee incorporated in England and Wales. The registered office is Unit 9, Oakhanger Farm Business Park, Oakhanger Road, Oakhanger, Hampshire, GU35 9JA.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

Covid-19

The full impact following the recent emergence of the global coronavirus pandemic is still unknown. It is therefore not currently possible to evaluate all the potential implications for the charity's activities, suppliers, beneficiaries and the wider economy at the date of approval of these financial statements. However, the trustees are closely monitoring the impact of COVID-19 on the charity.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2021 £	2021 £	2021 £	2020 £	2020 £	2020 £
Donations and gifts	725,410	21,790	747,200	501,104	623,639	1,124,743
Grants receivable for core activities	-	-	-	31,000	-	31,000
	<u>725,410</u>	<u>21,790</u>	<u>747,200</u>	<u>532,104</u>	<u>623,639</u>	<u>1,155,743</u>

4 Charitable activities

	Grants 2021 £	Grants 2020 £
Performance related grants	-	33,455
Government Grant	-	58,781
	<u>-</u>	<u>92,236</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

5 Investments

	Unrestricted funds	Unrestricted funds
	2021 £	2020 £
Interest receivable	54	801

6 Other trading activities

	Unrestricted funds	Unrestricted funds
	2021 £	2020 £
Sales of merchandise	6,963	7,697

7 Raising funds

	Unrestricted funds	Unrestricted funds	Restricted funds	Total
	2021 £	2020 £	2020 £	2020 £
<u>Fundraising and publicity</u>				
Fundraising costs	123,185	46,773	-	46,773
Staff costs	146,382	165,990	37,849	203,839
Depreciation and impairment	5,725	5,096	-	5,096
Support costs	38,308	37,103	-	37,103
Fundraising and publicity	313,600	254,962	37,849	292,811
<u>Trading costs</u>				
Other trading activities	14,483	15,804	-	15,804
	328,083	270,766	37,849	308,615

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

8 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/ information	Total 2021	Total 2020
	2021 £	2021 £	2021 £	2021 £	£	£
Staff costs	141,581	30,469	16,453	15,536	204,039	231,294
Depreciation and impairment	6,752	1,453	785	741	9,731	10,419
Other costs	163,389	34,933	18,863	17,813	234,998	120,279
	<u>311,722</u>	<u>66,855</u>	<u>36,101</u>	<u>34,090</u>	<u>448,768</u>	<u>361,992</u>
Share of support costs (see note 9)	38,151	8,210	4,433	4,187	54,981	59,963
Share of governance costs (see note 9)	7,026	1,512	816	770	10,125	15,883
	<u>356,899</u>	<u>76,577</u>	<u>41,350</u>	<u>39,047</u>	<u>513,874</u>	<u>437,838</u>
Analysis by fund						
Unrestricted funds	237,611	55,390	32,377	21,059	346,437	312,399
Restricted funds	119,288	21,188	8,973	17,988	167,437	125,439
	<u>356,899</u>	<u>76,578</u>	<u>41,350</u>	<u>39,047</u>	<u>513,874</u>	<u>437,838</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

8 Charitable activities

(Continued)

For the year ended 31 December 2020

	Raising awareness	Supporting research	Medical education	Patient support/information	Total 2020
	£	£	£	£	£
Staff costs	133,330	39,581	18,624	39,759	231,294
Depreciation and impairment	5,982	1,817	836	1,784	10,419
Other costs	67,989	21,418	9,848	21,024	120,279
	<u>207,301</u>	<u>62,816</u>	<u>29,308</u>	<u>62,567</u>	<u>361,992</u>
Share of support costs (see note 9)	34,428	10,459	4,809	10,267	59,963
Share of governance costs (see note 9)	9,119	2,770	1,274	2,720	15,883
	<u>250,848</u>	<u>76,045</u>	<u>35,391</u>	<u>75,554</u>	<u>437,838</u>
Analysis by fund					
Unrestricted funds	181,974	52,981	26,558	50,886	312,399
Restricted funds	68,874	23,064	8,833	24,668	125,439
	<u>250,848</u>	<u>76,045</u>	<u>35,391</u>	<u>75,554</u>	<u>437,838</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

9 Support costs

	Support costs	Governance costs	2021 Support costs	Governance costs	2020
	£	£	£	£	£
Rent	26,878	-	26,878	48,062	48,062
Office costs	9,672	-	9,672	3,076	3,076
Telephone costs	2,862	-	2,862	6,589	6,589
Computer costs	20,312	-	20,312	21,609	21,609
Insurance	3,199	-	3,199	3,758	3,758
Training, recruitment and internship costs	22,005	-	22,005	1,988	1,988
Book-keeping and Accountancy	2,016	-	2,016	1,747	1,747
Bank charges	392	-	392	2,468	2,468
Audit fees	-	10,680	10,680	-	6,960
Legal and professional	-	5,398	5,398	-	16,692
	<u>87,336</u>	<u>16,078</u>	<u>103,414</u>	<u>89,297</u>	<u>112,949</u>
Analysed between					
Fundraising	32,355	5,953	38,308	29,334	37,103
Charitable activities	54,981	10,125	65,106	59,963	75,846
	<u>87,336</u>	<u>16,078</u>	<u>103,414</u>	<u>89,297</u>	<u>112,949</u>

Governance costs include payments to the auditor of £8,520 (2020 - £4,920) for audit fees and £2,160 (2020 - £2,040 for accounts preparation fees)

10 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2020- £Nil).

11 Employees

The average monthly number of employees during the year was:

2021 Number	2020 Number
<u>11</u>	<u>13</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

11 Employees (Continued)

Employment costs	2021 £	2020 £
Wages and salaries	314,528	392,647
Social security costs	26,329	31,655
Other pension costs	9,564	10,831
	<u>350,421</u>	<u>435,133</u>

From April 2021 to 16th September 2021, the CEO salary was reduced by 50%.

The number of employees whose annual remuneration was £60,000 or more were:

	2021 Number	2020 Number
£60,000 - £70,000	<u>0</u>	<u>0</u>

12 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

13 Tangible fixed assets

	Fixtures, fittings & equipment £	Computers £	Total £
Cost			
At 1 January 2021	31,237	41,911	73,148
Disposals	(20,625)	(29,667)	(50,292)
At 31 December 2021	<u>10,612</u>	<u>12,244</u>	<u>22,856</u>
Depreciation and impairment			
At 1 January 2021	22,378	32,199	54,577
Depreciation charged in the year	7,609	7,845	15,454
Eliminated in respect of disposals	(20,625)	(29,667)	(50,292)
At 31 December 2021	<u>9,362</u>	<u>10,377</u>	<u>19,739</u>
Carrying amount			
At 31 December 2021	<u>1,250</u>	<u>1,867</u>	<u>3,117</u>
At 31 December 2020	<u>8,859</u>	<u>9,712</u>	<u>18,571</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

14 Stocks

	2021 £	2020 £
Finished goods and goods for resale	18,411	14,892

15 Debtors

	2021 £	2020 £
Amounts falling due within one year:		
Trade debtors	250	-
Other debtors	258	278
Prepayments and accrued income	50,069	113,047
	50,577	113,325

16 Creditors: amounts falling due within one year

	2021 £	2020 £
Other taxation and social security	11,028	30,432
Trade creditors	13,846	(6)
Accruals and deferred income	27,763	27,076
	52,637	57,502

17 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to the SOFA in respect of defined contribution schemes was £9,564 (2020 - £10,831).

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

18 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 1 January 2021	Incoming resources	Resources expended	Balance at 31 December 2021
	£	£	£	£	£	£	£
Pat & Paul	-	1,366	-	1,366	1,140	-	2,506
POW app	17,200	-	-	17,200	-	-	17,200
Recipe Book	20,110	-	-	20,110	-	(1,936)	18,174
Patient Information Booklets	27,137	-	(9,150)	17,987	-	(2,015)	15,972
Hope is Contagious	-	6	-	6	150	-	156
NIPanC	-	14,706	(8,250)	6,456	-	-	6,456
PC Aware Wales	3,500	24,245	-	27,745	-	(27,745)	-
Hard to reach groups	-	6,000	-	6,000	-	(6,000)	-
Pancreatic Cancer Scotland	-	607,560	(87,106)	520,454	18,500	(127,491)	411,463
HMRC JRS Grant	-	58,782	(58,782)	-	-	-	-
Health information officer	-	2,250	-	2,250	-	(2,250)	-
Community volunteers	-	960	-	960	-	-	960
GP Packs	-	-	-	-	2,000	-	2,000
	<u>67,947</u>	<u>715,875</u>	<u>(163,288)</u>	<u>620,534</u>	<u>21,790</u>	<u>(167,437)</u>	<u>474,887</u>

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

19 Analysis of net assets between funds

	Unrestricted 2021 £	Restricted 2021 £	Total 2021 £	Unrestricted 2020 £	Restricted 2020 £	Total 2020 £
Fund balances at 31 December 2021 are represented by:						
Tangible assets	3,117	-	3,117	18,571	-	18,571
Current assets/(liabilities)	364,193	474,887	839,080	290,832	620,534	911,366
	<u>367,310</u>	<u>474,887</u>	<u>842,197</u>	<u>309,403</u>	<u>620,534</u>	<u>929,937</u>

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

20 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 January 2020	Resources expended	Balance at 1 January 2021	Resources expended	Balance at 31 December 2021
	£	£	£	£	£
Early diagnosis challenge award (research)	17,107	(1,622)	15,485	(13,410)	2,075
	<u>17,107</u>	<u>(1,622)</u>	<u>15,485</u>	<u>(13,410)</u>	<u>2,075</u>

21 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £46,897 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

22 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2021 £	2020 £
Within one year	<u>4,320</u>	<u>23,423</u>

23 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2021 £	2020 £
Aggregate compensation	<u>44,921</u>	<u>42,512</u>

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

24	Cash generated from operations	2021 £	2020 £
	(Deficit)/surplus for the year	(87,740)	510,024
	Adjustments for:		
	Investment income recognised in statement of financial activities	(54)	(801)
	Depreciation and impairment of tangible fixed assets	15,455	15,515
	Movements in working capital:		
	(Increase)/decrease in stocks	(3,519)	14,564
	Decrease/(increase) in debtors	62,748	(28,986)
	(Decrease)/increase in creditors	(4,865)	22,574
	Cash (absorbed by)/generated from operations	(17,975)	532,890
25	Analysis of changes in net funds		
	The charity had no debt during the year.		